Lotus Eye Hospital And Institute Ltd

Lotus Eye Hospital And Institute Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure, effective from July 1, 2026, is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The date of the board meeting to approve these results will be communicated separately.

Lotus Eye Hospital And Institute Ltd announced its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 26, 2026. Additionally, Mr. P Vishnu Adithan, Chartered Accountant, has been reappointed as the Internal Auditor for the financial year 2026-27. The meeting commenced at 05:15 PM and concluded at 06:00 PM.

Lotus Eye Hospital And Institute Ltd reappointed Mr. P Vishnu Adithan, Chartered Accountant, as the Internal Auditor for the financial year 2026-27. The decision was made during a Board of Directors meeting held on May 26, 2026, where the standalone audited financial results for the quarter and year ended March 31, 2026, were also approved. The meeting commenced at 05:15 PM and concluded at 06:00 PM.

Lotus Eye Hospital And Institute Ltd announced its standalone audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 26, 2026. Mr. P Vishnu Adithan, Chartered Accountant, was reappointed as Internal Auditor for FY 2026-27. The meeting commenced at 05:15 PM and concluded at 06:00 PM.

Lotus Eye Hospital And Institute Ltd has scheduled a Board of Directors meeting on May 26, 2026, to consider and approve the Standalone Audited Financial Results for the quarter and year ended March 31, 2026. The trading window will reopen 48 hours after the declaration of the financial results, in accordance with SEBI (PIT) Regulations, 2015.

Sangeetha Sundaramoorthy acquired additional shares of Lotus Eye Hospital And Institute Limited through an inter-se transfer, as per Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Her holding increased from 28.1391% (58,51,901 shares) to 35.0084% post acquisition. The equity share capital of Lotus Eye remains at ₹20,79,63,300.

Lotus Eye Hospital and Institute Ltd. has announced the closure of its trading window for dealing in the company's equity shares by designated persons and their immediate relatives. This closure is in accordance with SEBI (PIT) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading. The trading window will remain closed from April 1, 2026, till the end of 48 hours after the declaration of the Audited Financial Results for the quarter and financial year ended March 31, 2026. The date of the Board Meeting for the approval of these results will be intimated in due course.

In a recent Board Meeting held on March 17, 2026, the Board of Directors of Lotus Eye Hospital and Institute Ltd. decided not to proceed with the voluntary delisting of the Company's equity shares from the National Stock Exchange of India Limited (NSE). This decision was made considering the current market conditions, liquidity factors, and the intent to ensure continued investor convenience and flexibility. The Company will continue to remain listed on both the BSE Limited and National Stock Exchange of India Limited.

Lotus Eye Hospital And Institute Ltd has informed BSE that a meeting of the Board of Directors is scheduled on March 17, 2026. The agenda includes considering a proposal for voluntary delisting of the Company’s equity shares from the National Stock Exchange of India Limited (NSE) in terms of the SEBI (Delisting of Equity Shares) Regulations, 2021. The Company will continue to remain listed on BSE Limited.

Lotus Eye Hospital and Institute Ltd. has been imposed a fine of Rs.2,17,120 each by BSE Limited and National Stock Exchange of India Limited. This is in accordance with Schedule III of SEBI (LODR) Regulations, 2015 due to non-compliance of Regulation 17(1A). The company has already rectified this non-compliance pursuant to approval of the shareholders through Postal Ballot. The fine does not have a material impact on the financial operations of the listed entity.